Science Explorer Back to mapMap
Discussion

Currax Pharmaceuticals (United States)

Research works
2
▲ 54% vs 2018-21
Citations
27
15.2 per fractional work
Top-10% rate
20.4%
all institutions 10.0%
Open access
86%
world 40%
International
58%
world 18%
Currax Pharmaceuticals (United States)

Not ranked overall: Currax Pharmaceuticals (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Currax Pharmaceuticals (United States) work in?

In all years, 59% of research at Currax Pharmaceuticals (United States) is in Health Sciences, 24% in Life Sciences. Its largest fields are Medicine (59%), Neuroscience (24%), Psychology (18%).

Life Sciences24%Health Sciences59%Social Sciences18%

Each ring splits the one inside it: the four domains of science, their fields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 3 fields, with their numbers
    1. Medicine158.8%
    1. Neuroscience023.5%
    1. Psychology017.6%
All of science, and how each field's share has moved since 1950: the Science domain explorer

What are the most cited papers from Currax Pharmaceuticals (United States)?

The most cited paper from Currax Pharmaceuticals (United States) is "The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy" (Carel Wynand le Roux, Nadège Fils‐Aimé, Fernando Camacho et al., 2022), with 30 citations. Next come "Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials" (27) and "Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight" (23).

Most cited papers
#PaperReleasedCitations
1 The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy Carel Wynand le Roux, Nadège Fils‐Aimé, Fernando Camacho et al. · EClinicalMedicine Open access 27 May 2022 30
2 Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials HARPREET SINGH BAJAJ, Melonie Burrows, Jessica Blavignac et al. · Diabetes Obesity and Metabolism 4 Dec 2020 27
3 Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight Roger S. McIntyre, Emilia Paron, Melonie Burrows et al. · Journal of Affective Disorders Open access 23 Apr 2021 23
4 Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial Sean Wharton, Peter Yin, Melonie Burrows et al. · International Journal of Obesity Open access 3 Jun 2021 12
5 Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review Sarah Dahlberg, Ellen T. Chang, Sheila R. Weiss et al. · Diabetes Metabolic Syndrome and Obesity ReviewOpen access Sep 2022 10
All 6 most cited papers, with filters and sorting

Which research topics does Currax Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Sleep and Wakefulness Research, Sleep and related disorders, Pharmacology and Obesity Treatment and Neurotransmitter Receptor Influence on Behavior.

  1. 1 Sleep and Wakefulness Research Cognitive Neuroscience 0 works
  2. 2 Sleep and related disorders Experimental and Cognitive Psychology 0 works
  3. 3 Pharmacology and Obesity Treatment Pharmacology 0 works
  4. 4 Neurotransmitter Receptor Influence on Behavior Cellular and Molecular Neuroscience 0 works
  5. 5 Bariatric Surgery and Outcomes Surgery 0 works
  6. 6 Opioid Use Disorder Treatment Public Health, Environmental and Occupational Health 0 works
  7. 7 Cardiovascular Syncope and Autonomic Disorders Surgery 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available86.0%not open14.0%

World: 40% of research is openly available.

with international co-authors57.9%domestic only42.1%

World: 18% is written across borders.

How has Currax Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 54% higher than in 2018-2021.

Other research institutions in Morristown

All research institutions in Morristown

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Currax Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.